



01-17-06

*[Handwritten signature]*

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig A. Coburn et al.	
Serial No.:	10/534,291 ✓	Case No.: 21145YP
US Nat'l Filing Date:	May 9, 2005	
Int'l Appl'n No.	PCT/US03/35316	
Int'l Filing Date:	6 November 2003	
For:	PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

MAIL STOP PCT  
Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT January 13, 2006  
EXPRESS MAIL NO. 9546011405

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,  
Alexandria, Virginia 22313-1450

MAILED BY Christina Cuffe  
DATE 1-13-06


This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: January 13, 2006

## STATEMENT BY APPLICANT

use as many sheets as necessary)

**1**

of

<b>Application Number</b>	10/534,291
---------------------------	------------

May 9, 2005

<b>First Named Inventor</b>	Craig A. Coburn et al.
-----------------------------	------------------------

Group Art Unit	To Be Assigned
----------------	----------------

Examiner Name	To Be Assigned
---------------	----------------

Attorney Docket Number	21145YP
------------------------	---------

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	AA		CA 2,328,720		BASF AKTIENGESSELLSCHAFT	10/28/1999
	BB		DE 198 18 614		BASF AG	10/21/1999
	CC		DE 198 17 461		BASF AG	10/21/1999
	DD		DE 196 50 975		BASF AG	06/10/1998
	EE		WO 02/02518		Elan Pharmaceuticals, Inc.	01/10/2002
	FF		WO 02/002518		Elan Pharmaceuticals, Inc.	01/10/2002
	GG		WO 02/02505		Elan Pharmaceuticals, Inc.	01/10/2002
	HH		WO 01/70672		Elan Pharmaceuticals, Inc.	09/27/2001
	II		WO 02/02506		Elan Pharmaceuticals, Inc.	01/10/2002
	JJ		WO 02/02520		Elan Pharmaceuticals, Inc.	01/10/2002

Date  
Considered

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

### STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/534,291
<b>Filing Date</b>	May 9, 2005
<b>First Named Inventor</b>	Craig A. Coburn et al.
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
<b>Attorney Docket Number</b>	21145YP

Sheet	2	of	3
-------	---	----	---

[illegible][illegible]

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

## STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/534,291
<b>Filing Date</b>	May 9, 2005
<b>First Named Inventor</b>	Craig A. Coburn et al.
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
<b>Attorney Docket Number</b>	21145YP

Sheet	3	of	3
-------	---	----	---

## NON PATENT LITERATURE DOCUMENTS

Examiner  
Initials\*Cite  
No.

**Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.**

AAA

Moore et al., "Difluoro Ketone Peptidomimetics Suggest a Large S1 Pocket for Alzheimer's gamma-Secretase: Implications for Inhibitor Design," J. Med. Chem., Vol. 43, pp. 3434-3442 (2000)

BBB

Shearman et al., "L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid beta-Protein Precursor gamma-Secretase Activity," *Biochemistry*, Vol. 39, pp. 8698-8704 (2000)

CCC

Li et al., "Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1," Letter to Nature, Vol. 405, pp. 689-694 (2000)

DDD

Barrish et al., "Aminodiol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SAR," J. Med. Chem., Vol. 37, pp. 1758-1768 (1994)

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005